New Border Measures (31) (Review on the requirement of the certificate of negative result of pre-departure test)
2022/8/25
New Border Measures (31)
(Review on the requirement of the certificate of negative result of pre-departure test)
(Review on the requirement of the certificate of negative result of pre-departure test)
August 25, 2022
1. Review on the requirement of the certificate of negative result of pre-departure test
Based on New Border Measures (9) (March 5, 2021), all cross-border travelers and returnees continue to be required, for the time being, to submit a certificate of negative test result of pre-departure COVID-19 test conducted within 72 hours prior to departure from the original country/region.
Among those entrants, however, for all cross-border travelers and returnees from countries/regions where the B.1.1.529 Omicron variant becomes dominant (all countries/regions except for those where COVID-19 variants other than the Omicron variant become dominant, based on the New Border Measures (27) (February 24, 2022)) designated in the paragraph 1 of the New Border Measures (28) (May 20, 2022) (hereinafter referred to as “the Measures (28)”), persons with a valid vaccination certificate of COVID-19 (validity of which is certified by the Ministry of Foreign Affairs (MOFA) and the Ministry of Health, Labour and Welfare (MHLW)) and which proves that three doses of COVID-19 vaccine stipulated in the Annex 2 of the Measures (28) are inoculated. Hereinafter referred to as “vaccination certificate”.) will be no longer required to submit the certificate of negative test result of pre-departure COVID-19 test within 72 hours prior to departure from the original country/region.
(Note 1) The abovementioned measures will be implemented from 0:00 AM (JST) on September 7, 2022.
(END)
(Annex 2)
Regarding COVID-19 vaccination certificates recognized as valid
in application of the New Border Measures (28)
in application of the New Border Measures (28)
August 25, 2022
In applying measures based on New Border Measures (28) (May 20, 2022), COVID-19 vaccination certificates recognized as valid, in principle, fall under any of the categories 1 or 2 below.
1. COVID-19 vaccination certificates issued in Japan which fall under any of the categories (1)-(3) below, and prove that at least three doses of COVID-19 vaccine are inoculated.
(1) COVID-19 vaccination certificates issued by either the Government of Japan or a local public authority/municipality in Japan (The COVID-19 Vaccination Certificate for overseas travel)
(2) Documents to prove vaccination for COVID-19 issued by a local public authority/municipality in Japan
(3) Records of Vaccination for COVID-19 issued by medical institutions in Japan
2. COVID-19 vaccination certificates issued abroad which fulfill all the three requirements (1)-(3) below.
(1) All relevant items described below should be listed on the certificate either in Japanese or English:
Name, date of birth, product name or manufacturer of vaccines, vaccination date, number of COVID-19 vaccine doses (Note 1)
(Note 1) COVID-19 vaccination certificates written in languages other than Japanese or English are considered as valid if the translation (Japanese/English) is attached and all the items are clearly identifiable.
(2) The certificate should prove that at least two doses (as for JCOVDEN, intramuscular injection / Janssen, one dose is counted as two doses) of any of the COVID-19 vaccines described in the table a. below are inoculated, and any of the COVID-19 vaccines described in the table b. below is inoculated for the third vaccination or after. (Note 2)
a. COVID-19 vaccines up to the second dose:
Product Name or Manufacturer | Designated Date | Abolished Date |
COMIRNATY, intramuscular injection / Pfizer (Note 3) | May 20, 2022 | |
Vaxzevria, intramuscular injection / AstraZeneca (Note 3) | May 20, 2022 | |
Spikevax, intramuscular injection / Moderna | May 20, 2022 | |
JCOVDEN, intramuscular injection / Janssen | May 20, 2022 | |
COVAXIN / Bharat Biotech | May 20, 2022 | |
Nuvaxovid, intramuscular injection / Novavax (Note 3) | May 20, 2022 |
(Note 3) In applying measures based on New Border Measures (28), COMIRNATY manufactured by Fosun Pharma / BioNTech and Covishield / COVOVAX manufactured by the Serum Institute of India are treated as identical to COMIRNATY, intramuscular injection / Pfizer, Vaxzevria, intramuscular injection / AstraZeneca and Nuvaxovid, intramuscular injection / Novavax, respectively.
b. COVID-19 vaccines for the third dose or after:
Product Name or Manufacturer | Designated date | Abolished date |
COMIRNATY, intramuscular injection / Pfizer (Note 4) | May 20, 2022 | |
Spikevax, intramuscular injection / Moderna | May 20, 2022 | |
Nuvaxovid, intramuscular injection / Novavax (Note 4) | May 20, 2022 | |
Vaxzevria, intramuscular injection / AstraZeneca (Note 4) | June 22, 2022 | |
JCOVDEN, intramuscular injection / Janssen | June 22, 2022 | |
COVAXIN / Bharat Biotech | July 27, 2022 |
(3) The certificate should be issued by an official body, such as a government.